Mitokondriyal Hastalıklar
Özet
Mitokondriyal hastalıklar, mitokondriyal fonksiyon bozukluğuna yol açan genetik mutasyonlarla karakterize, çoklu organ tutulumu gösterebilen heterojen bir hastalık grubudur. Hücresel enerji üretimi ve diğer kritik metabolik yolaklardaki aksaklıklar, klinik tablonun ciddiyetini belirleyen temel faktörlerdir. Tanı süreci; klinik semptomların, metabolik tetkiklerin ve genetik analizlerin entegrasyonunu gerektiren oldukça zorlu bir süreçtir. Güncel olarak özgün bir kür bulunmadığı için tedavide destekleyici beslenme ve semptomatik müdahaleler temel yaklaşımı oluşturur.
Mitochondrial diseases comprise a heterogeneous group of genetic disorders characterized by mitochondrial dysfunction involving both nuclear and mitochondrial DNA. These conditions often present with diverse, multi-systemic symptoms due to impaired ATP production and other critical metabolic pathways. Diagnostic evaluation is complex, necessitating the integration of clinical findings, metabolic markers, and genetic testing. Currently, there is no curative treatment available, with therapeutic approaches largely limited to symptomatic management and supportive care.
Referanslar
Gorman GS, Chinnery PF, DiMauro S, et al. Mitochondrial diseases. Nat Rev Dis Primers. 2016; 2:16080.
Alston CL, Rocha MC, Lax NZ, et al. The genetics and pathology of mitochondrial disease. J Pathol. 2017;241(2):236-250.
Kühlbrandt, W. Structure and function of mitochondrial membrane protein complexes. BMC Biol 13, 89 (2015).
Rahman S, Mayr JA. Disorders of Oxydative Phosphorylation. Saudubray JM, Matthias RB, Walter J. (Eds). Inborn Metabolic Diseases Diagnosis and Treatment. 6th ed. Heidelberg: Springer; 2016. p.224-242.
Jameson E, Morris A. A. M., Mitochondrial disease – a review. Paediatrics and Child Health. 2011; 21(2), 80–83.
Gorman GS, Schaefer AM, Ng Y, et al. Prevalence of nuclear and mitochondrial DNA mutations related to adult mitochondrial disease. Ann Neurol 2015; 77: 753–759.
Skladal D, Halliday J, Thorburn DR. Minimum birth prevalence of mitochondrial respiratory chain disorders in children. Brain 2003; 126: 1905–1912.
Rahman S. Mitochondrial disease in children. J Intern Med. 2020;287(6):609-633.
Schon KR, Ratnaike T, van den Ameele J, et al. Mitochondrial Diseases: A Diagnostic Revolution. Trends Genet. 2020;36(9):702-717.
Muraresku CC, McCormick EM, Falk MJ. Mitochondrial Disease: Advances in clinical diagnosis, management, therapeutic development, and preventative strategies. Curr Genet Med Rep. 2018;6(2):62-72.
Barbetti F, Ghizzoni L, Guaraldi F (eds): Diabetes Associated with Single Gene Defects and Chromosomal Abnormalities. Front Diabetes. Basel, Karger, 2017, vol 25, pp 55-68.
van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet. 1992;1:368–71.
Fassone E, Rahman S. Complex I deficiency: Clinical features, biochemistry and molecular genetics. J Med Genet 2012; 49: 578–90.
Glamuzina E, Brown R, Hogarth K et al. Further delineation of pontocerebellar hypoplasia type 6 due to mutations in the gene encoding mitochondrial arginyl-tRNA synthetase, RARS2. J Inherit Metab Dis 2012; 35: 459–67.
Vu TH, Sciacco M, Tanji K, et al. Clinical manifestations of mitochondrial DNA depletion. Neurology. 1998;50(6):1783-1790.
Rahman S, Poulton J. Diagnosis of mitochondrial DNA depletion syndromes. Arch Dis Child 2009; 94: 3–5.
Elpeleg O, Miller C, Hershkovitz E, et al. Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion. Am J Hum Genet. 2005;76(6):1081-1086.
Viscomi C, Zeviani M. MtDNA-maintenance defects: syndromes and genes. J Inherit Metab Dis. 2017;40(4):587-599.
Rahman S, Copeland WC. POLG-related disorders and their neurological manifestations. Nat Rev Neurol. 2019;15(1):40-52.
Keshavan N, Abdenur J, Anderson G, et al. The natural history of infantile mitochondrial DNA depletion syndrome due to RRM2B deficiency. Genet Med. 2020;22(1):199-209.
Kasapkara ÇS, Tümer L, Küçükçongar A, et al. DGUOK-Related Mitochondrial DNA Depletion Syndrome in a Child With an Early Diagnosis of Glycogen Storage Disease, Journal of Pediatric Gastroenterology and Nutrition: November 2013-Volume 57-Issue 5- p e28-e29.
Ünal Ö, Hişmi B, Kılıç M, et al. Deoxyguanosine kinase deficiency: a report of four patients. Journal of Pediatric Endocrinology and Metabolism. 2017;30(6): 697-702.
Maertens, P. Mitochondrial encephalopathies. Seminars in Pediatric Neurology, (1996) 3(4), 279–297.
Lake NJ, Bird MJ, Isohanni P, et al. Leigh syndrome: neuropathology and pathogenesis. J Neuropathol Exp Neurol. 2015;74(6):482-492.
Rahman S, Blok RB, Dahl HH, et al. Leigh syndrome: Clinical features and biochemical and DNA abnormalities. Ann Neurol 1996; 39:343-351
Leigh D. Subacute necrotizing encephalomyelopathy in an infant. J Neurol Neurosurg Psychiatry 1951; 14:216-221
van Erven PM, Cillessen JP, Eekhoff EM, et al. Leigh syndrome, a mitochondrial encephalo(myo)pathy. A review of the literature. Clin Neurol Neurosurg 1987; 89:217-230
Sofou K, De Coo IF, Isohanni P, et al. A multicenter study on Leigh syndrome: Disease course and predictors of survival. Orphanet J Rare Dis 2014; 9:52
Ma YY, Wu TF, Liu YP, et al. Genetic and biochemical findings in Chinese children with Leigh syndrome. J Clin Neurosci 2013; 20:1591-1594
Rahman S. Mitochondrial disease and epilepsy. Dev Med Child Neurol. 2012;54(5):397-406.
Quinzii C, M, Emmanuele V, Hirano M: Clinical Presentations of Coenzyme Q10 Deficiency Syndrome. Mol Syndromol 2014; 5:141-146.
Lin CM, Thajeb P. Valproic acid aggravates epilepsy due to MELAS in a patient with an A3243G mutation of mitochondrial DNA. Metab Brain Dis 2007; 22: 105–109.
Lam CW, Lau CH, Williams JC, et al. Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy. Eur J Pediatr 1997; 156: 562–564.
Galimberti CA, Diegoli M, Sartori I, et al. Brain pseudoatrophy and mental regression on valproate and a mitochondrial DNA mutation. Neurology 2006; 67: 1715–1717.
Chabrol B, Mancini J, Chretien D, et al. Valproate-induced hepatic failure in a case of cytochrome c oxidase deficiency. Eur J Pediatr 1994; 153: 133–135.
Mancuso M, Galli R, Pizzanelli C, et al. Antimyoclonic effect of levetiracetam in MERRF syndrome. J Neurol Sci 2006; 243: 97–99.
Arpin S, Lagrue E, Bodard S, et al. Basal ganglia neuroprotection with anticonvulsants after energy stress: a comparative study. Metab Brain Dis 2009; 24: 453– 461.
Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009; 47: 101–111.
Parikh S, Goldstein A, Koenig MK, et al. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genet Med. 2015;17(9):689-701.
Haas RH, Parikh S, Falk MJ, et al. The in-depth evaluation of suspected mitochondrial disease. Mol Genet Metab. 2008; 94:16–37.
Debray FG, Mitchell GA, Allard P, et al. Diagnostic accuracy of blood lactate-to-pyruvate molar ratio in the differential diagnosis of congenital lactic acidosis. Clin Chem. 2007; 53:916–921.
Patel KP, O’Brien TW, Subramony SH, et al. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab. 2012; 106:385–394.
Barshop BA. Metabolomic approaches to mitochondrial disease: correlation of urine organic acids. Mitochondrion. 2004; 4:521–527.
Wortmann SB, Rodenburg RJ, Jonckheere A, et al. Biochemical and genetic analysis of 3- methylglutaconic aciduria type IV: a diagnostic strategy. Brain. 2009; 132(Pt 1):136–146.
Barshop BA, Nyhan WL, Naviaux RK, et al. Kearns-Sayre syndrome presenting as 2-oxoadipic aciduria. Mol Genet Metab. 2000; 69:64–68.
Sakamoto O, Ohura T, Murayama K, et al. Neonatal lactic acidosis with methylmalonic aciduria due to novel mutations in the SUCLG1 gene. Pediatr Int. 2011; 53:921–925.
Gillis LA, Sokol RJ. Gastrointestinal manifestations of mitochondrial disease. Gastroenterol Clin North Am. 2003;32(3):789-v.
Saneto RP, Friedman SD, Shaw DW. Neuroimaging of mitochondrial disease. Mitochondrion. 2008; 8:396–413.
Valanne L, Ketonen L, Majander A, et al. Neuroradiologic findings in children with mitochondrial disorders. AJNR Am J Neuroradiol. 1998; 19:369–377.
Scheper GC, van der Klok T, van Andel RJ, et al. Mitochondrial aspartyl-tRNA synthetase deficiency causes leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation. Nat Genet. 2007; 39:534–539.
Steenweg ME, Ghezzi D, Haack T, et al. Leukoencephalopathy with thalamus and brainstem involvement and high lactate ‘LTBL’ caused by EARS2 mutations. Brain. 2012; 135(Pt 5):1387– 1394.
van Berge L, Hamilton EM, Linnankivi T, et al. Leukoencephalopathy with brainstem and spinal cord involvement and lactate elevation: clinical and genetic characterization and target for therapy. Brain. 2014; 137:1019–1029
McDonnell MT, Schaefer AM, Blakely EL, et al. Noninvasive diagnosis of the 3243A > G mitochondrial DNA mutation using urinary epithelial cells. Eur J Hum Genet. 2004; 12:778–781.
Whittaker RG, Blackwood JK, Alston CL, et al. Urine heteroplasmy is the best predictor of clinical outcome in the m.3243A>G mtDNA mutation. Neurology. 2009; 72:568–569.
Cui H, Li F, Chen D, et al. Comprehensive next-generation sequence analyses of the entire mitochondrial genome reveal new insights into the molecular diagnosis of mitochondrial DNA disorders. Genet Med. 2013; 15:388–394.
Wong LJ. Next generation molecular diagnosis of mitochondrial disorders. Mitochondrion. 2013; 13:379–387.
Ng YS, Turnbull DM. Mitochondrial disease: genetics and management. J Neurol. 2016;263(1):179-191.
Pfeffer G, Majamaa K, Turnbull DM, et al. Treatment for mitochondrial disorders. Cochrane Database Syst Rev. 2012;2012(4):CD004426.
Klopstock T, Yu-Wai-Man P, Dimitriadis K, et al. A randomized placebo-controlled trial of idebenone in Leber's hereditary optic neuropathy. Brain. 2011;134(Pt 9):2677-2686.
Emmanuele V, López LC, Berardo A, et al. Heterogeneity of coenzyme Q10 deficiency: patient study and literature review [published correction appears in Arch Neurol. 2012 Jul;69(7):886. López, Luis [corrected to López, Luis C]]. Arch Neurol. 2012;69(8):978-983.
Koga Y, Akita Y, Nishioka J, et al. L-arginine improves the symptoms of strokelike episodes in MELAS. Neurology. 2005;64(4):710-712.
Garone C, Tadesse S, Hirano M. Clinical and genetic spectrum of mitochondrial neurogastrointestinal encephalomyopathy. Brain. 2011;134(Pt 11):3326-3332.
Sicurelli F, Carluccio MA, Toraldo F, et al. Clinical and biochemical improvement following HSCT in a patient with MNGIE: 1-year follow-up. J Neurol. 2012;259(9):1985-1987.
Yadak R, Sillevis Smitt P, van Gisbergen MW, et al. Mitochondrial Neurogastrointestinal Encephalomyopathy Caused by Thymidine Phosphorylase Enzyme Deficiency: From Pathogenesis to Emerging Therapeutic Options. Front Cell Neurosci. 2017;11:31.
Torres-Torronteras J, Cabrera-Pérez R, Vila-Julià F, et al. Long-Term Sustained Effect of Liver-Targeted Adeno-Associated Virus Gene Therapy for Mitochondrial Neurogastrointestinal Encephalomyopathy. Hum Gene Ther. 2018;29(6):708-718.
Zhang Y, Tian Z, Yuan J, et al. The Progress of Gene Therapy for Leber's Optic Hereditary Neuropathy. Curr Gene Ther. 2017;17(4):320-326.
